Six things to know:
1. Total revenue decreased 8 percent year over year.
2. U.S. revenue, which is 51 percent of total sales, was $3.8 billion. International revenue was $2.3 billion, falling 10 percent from the previous year.
3. Cranial and spinal technologies had a 7 percent decrease, with $1 billion in sales.
4. The full neuroscience segment decreased 4 percent, with $2.1 billion revenue.
5. Medtronic maintains its guidance for fiscal year 2023 and expects full-year revenue to grow 4 to 5 percent.
6. Medtronic CEO Geoff Martha said: “The company continues to execute in a challenging environment, delivering organic revenue above our guidance. As we look ahead, our supply chain is improving, we have several near-term pipeline catalysts approaching, and we are confident in our ability to accelerate growth.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
